Tofacitinib in juvenile idiopathic arthritis

[...]their use does pose challenges in paediatric practice as they are exclusively injectable formulations. [...]an urgent unmet need for efficacious oral treatments for children with JIA who do not respond adequately to methotrexate remains. The trial met its primary endpoint of lower JIA flare rate by week 44 with tofacitinib (21 [29%] of 72 patients) versus placebo (37 [53%] of 70 patients) in patients with polyarticular course JIA (hazard ratio 0·46, 95% CI 0·27–0·79) and reported improvements in secondary endpoints related to disease activity and physical function. [...]evidence of the effect of tofacitinib on uveitis incidence or activity is not available and would be important in informing real-world treatment choices, both in polyarticular course JIA and more broadly.